STOCK TITAN
  1. Home
  2. News
  3. ARQT

Arcutis Biotherapeutics Inc - ARQT STOCK NEWS

Welcome to our dedicated news page for Arcutis Biotherapeutics (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arcutis Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arcutis Biotherapeutics's position in the market.

News
Arcutis Appoints David Topper as Chief Financial Officer
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) appoints David Topper as Chief Financial Officer, replacing John Smither. Topper brings extensive finance, M&A, and capital markets experience. He joins from Inmagene Biopharmaceuticals with a strong track record in leading capital market activities. Topper's appointment reflects Arcutis' focus on advancing innovation in immuno-dermatology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
management
-
News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. grants 58,500 restricted stock units to newly hired employees under the 2022 Inducement Plan, with a vesting period of four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.49%
Tags
none
-
News
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) will participate in the 23rd Annual Needham Virtual Healthcare Conference on April 8-11, 2024. The company's management will engage in a Fireside Chat on April 11, 2024, at 2:15 pm EDT. Investors can access the webcast on the company's website, with a replay available for 180 days post-conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.34%
Tags
conferences
News
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) promotes Todd Tucker to senior vice president and Chief Human Resources Officer, recognizing his contribution to building the company culture and workforce capabilities. With over 25 years of industry experience, Mr. Tucker's appointment aims to strengthen Arcutis' position in immuno-dermatology and enhance employee programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.96%
Tags
none
-
News
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. presented positive results from the INTEGUMENT-PED Phase 3 study of roflumilast cream 0.05% for children with atopic dermatitis at the AAD annual meeting. The cream met primary and secondary endpoints, showing significant improvement in EASI-75, vIGA-AD, and itch reduction. Roflumilast cream demonstrated consistent efficacy, safety, and tolerability in children aged 2 to 5, with potential for approval as a well-tolerated treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.96%
Tags
clinical trial
-
News
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. highlights new research revealing the gene expression profile of seborrheic dermatitis, a unique inflammatory skin disease with its own molecular signature. The study suggests distinct skin barrier disruption in seborrheic dermatitis, providing key insights into the immune response of the condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.96%
Tags
none
News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. grants 12,000 restricted stock units to new employees under the 2022 Inducement Plan. The units vest over four years, subject to continuous employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.22%
Tags
none
-
News
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) announced the closing of a public offering, selling 18,157,895 shares at $9.50 per share, raising approximately $172.5 million. The underwriters exercised their option to purchase additional shares, leading to a total gross proceeds before expenses. Various investment firms acted as lead managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
offering
-
News
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. to present new data at the 2024 AAD annual meeting on roflumilast cream and foam for dermatological conditions. The company showcases positive results from Phase 3 trials in atopic dermatitis, psoriasis, and seborrheic dermatitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.97%
Tags
none
News
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) will participate in the TD Cowen 44th Annual Health Care Conference with a Fireside Chat on March 4, 2024, at 2:10 pm ET. The webcast can be accessed on the company's website, with a replay available for 180 days post-conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.49%
Tags
conferences
Stock ARQT logo
Arcutis Biotherapeutics Inc

Nasdaq:ARQT

ARQT Rankings

#2437 Ranked by Market Cap
#5426 Ranked by Stock Gains
N/A Ranked by Dividends

ARQT Stock Data

1.16B
74.79M
2.5%
95.84%
16.75%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Westlake Village

About ARQT

arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.